Aleglitazar, a balanced PPARα/γ agonist, has no clinically relevant pharmacokinetic interaction with high-dose atorvastatin or rosuvastatin

Expert Opinion on Investigational Drugs

Volumn 20, Issue 1, 2011, Pages 3-12

  Foley Comer, Adam J ^a,b   Young, Anne Marie ^a   Russell Yarde, Fiona ^a   Jordan, Paul ^c  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b BIOLINERX LTD   (Israel)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

cardiovascular pharmacology; diabetes; drug interactions; pharmacokinetics; statins

Indexed keywords

ALEGLITAZAR; ATORVASTATIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSUVASTATIN;

ABDOMINAL DISTENSION; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEMATURIA; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; MYALGIA; NAUSEA; NORMAL HUMAN; NOSE CONGESTION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SORE THROAT; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER RESPIRATORY TRACT INFECTION;

ADOLESCENT; ADULT; AGED; AREA UNDER CURVE; CROSS-OVER STUDIES; DRUG INTERACTIONS; FEMALE; FLUOROBENZENES; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; OXAZOLES; PPAR ALPHA; PPAR GAMMA; PYRIMIDINES; PYRROLES; SULFONAMIDES; THIOPHENES; YOUNG ADULT;

EID: 78650262962     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.539559     Document Type: Article

References (25)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics - 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21-e181
2. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 2007;116:e148-304
3. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007;28:1598-660
4. Benardeau A, Benz J, Binggeli A, et al. Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes. Bioorg Med Chem Lett 2009;19:2468-73
5. Henry RR, Lincoff AM, Mudaliar S, et al. Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet 2009;374:126-35
6. Link E, Parish S, Armitage J, et al. SLCO1B1 variants and statin-induced myopathy - a genome-wide study. N Engl J Med 2008;359:789-99
7. Sanwald-Ducray P, Liogier D'ardhuy X, Jamois C, Banken L. Pharmacokinetics, pharmacodynamics, and tolerability of aleglitazar in patients with type 2 diabetes: results from a randomized, placebo-controlled clinical study. Clin Pharmacol Ther 2010;88:197-203
8. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152-60
9. Nawrocki JW, Weiss SR, Davidson MH, et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc 1995;15:678-82
10. Bachmakov I, Glaeser H, Fromm MF, Konig J. Interaction of oral antidiabetic drugs with hepatic uptake transporters: focus on organic anion transporting polypeptides and organic cation transporter 1. Diabetes 2008;57:1463-9
11. Cilla DD Jr, Whitfield LR, Gibson DM, et al. Multiple-dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG-CoA reductase, in healthy subjects. Clin Pharmacol Ther 1996;60:687-95
12. Posvar EL, Radulovic LL, Cilla DD Jr, et al. Tolerance and pharmacokinetics of single-dose atorvastatin, a potent inhibitor of HMG-CoA reductase, in healthy subjects. J Clin Pharmacol 1996;36:728-31
13. Li Y, Jiang X, Lan K, et al. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. Clin Ther 2007;29:2194-203
14. Newman C, Tsai J, Szarek M, et al. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol 2006;97:61-7
15. Shepherd J, Vidt DG, Miller E, et al. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program. Cardiology 2007;107:433-43
16. AstraZeneca Pharmaceuticals LP. Crestor® (rosuvastatin calcium) Tablets. US Prescribing Information. Wilmington, DE, October 2009
17. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61
18. Yamazaki M, Li B, Louie SW, et al. Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica 2005;35:737-53
19. Goosen TC, Bauman JN, Davis JA, et al. Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab Dispos 2007;35:1315-24
20. Wang JS, Neuvonen M, Wen X, et al. Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes. Drug Metab Dispos 2002;30:1352-6
21. Nozawa T, Sugiura S, Nakajima M, et al. Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity. Drug Metab Dispos 2004;32:291-4
22. Forst T, Wilhelm B, Pfutzner A, et al. Investigation of the vascular and pleiotropic effects of atorvastatin and pioglitazone in a population at high cardiovascular risk. Diab Vasc Dis Res 2008;5:298-303
23. Lewin AJ, Kipnes MS, Meneghini LF, et al. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 2004;26:379-89
24. Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006;296:2572-81
25. Sugamura K, Sugiyama S, Matsuzawa Y, et al. Benefit of adding pioglitazone to successful statin therapy in nondiabetic patients with coronary artery disease. Circ J 2008;72:1193-7